{"prompt": "['Date: June 30, 2020', 'Version: 8.0', 'Page: 19 of 52', 'Proportion of overall responders in the SYN-010 21 mg and 42 mg treatment groups versus', 'placebo.', 'Change from baseline for SYN-010, relative to placebo, in:', 'Weekly average score for worst abdominal pain at Weeks 1 through 12.', 'Weekly average number of CSBMs at Weeks 1 through 12.', 'Weekly average number of SBMs at Weeks 1 through 12.', 'Weekly average bloating score at Weeks 1 through 12.', 'Weekly average stool consistency (BSFS) at Weeks 1 through 12.', '4.3 Exploratory', 'For SYN-010 relative to placebo:', 'Proportion of patients with adequate relief27.', 'Change from baseline for SYN-010 in patient reported outcomes (PRO) using validated', 'questionnaires in the REDCap system.', 'Breath gas area-under-the-curve (AUC) (methane, hydrogen, and hydrogen sulfide) on', 'lactulose breath test at EOS compared to Screening.', 'Spot breath tests at Randomization, Day 28, and Day 56.', 'Comparison of serum cytokine levels at baseline and EOS - measuring for potential immune', 'or inflammatory signals to include the key cytokines of the Th1/Th2/Th17 pathways: IL-2, IL-', '4, IL-5, IL-9, IL-10, IL-13, IL-17, GM-CSF and IFN-y. Plus TNF-a, IL-12, IL-6, the two', 'chemokines IL-8 and MCP-1, and the gut cytokine IL-25.', 'Microbiome measurements in stool of bacteria (16S rRNA) and methanogens (qPCR).', '5. Study design and investigational plan', '5.1', 'Pre-treatment period', 'Screening and Pre-treatment Period (up to 17 days prior to the first dose of study drug):', 'During the Screening and Pre-treatment Period, patients will be provided an ID number and', 'password-protected access to the REDCap website to record baseline parameters (such as weekly', 'average worst abdominal pain score and weekly number of CSBMs). During this period, patients will', 'also (i) complete a lactulose breath test including analysis of methane, hydrogen, hydrogen sulfide,', 'and carbon dioxide; (ii) provide a stool sample for analysis of the microbiome; and (iii) provide a', 'blood sample for analysis of cytokines and baseline tests. Patients will be eligible for randomization', 'if they have a breath methane level of 10 ppm on the lactulose breath test and fully respond to', 'the PRO questionnaires in the REDCap system on at least 11 of 14 days of the Screening and Pre-', 'treatment Period.', '5.2', 'Treatment phase', 'Treatment Period comprising Randomization (Day 1) and 12 weeks of dosing (with clinic visits at', 'Weeks 4, 8, and 12).', 'On Day 1, eligible patients will be randomized in a 1:1:1 ratio to receive study drug (SYN-010 21 mg,', 'SYN-010 42 mg, or placebo). Study drug will be administered during the Treatment Period and taken', 'once daily at bedtime for up to 12 weeks.']['Date: June 30, 2020', 'Version: 8.0', 'Page: 20 of 52', '5.3', 'Post-treatment period or follow-up period', 'End-of-Study contact between 24 and 48 hours after Week 12 for patients who complete the', 'Treatment Period.', '6. Statistical methods and determination of sample size', '6.1', 'General considerations', 'A statistical analysis plan (SAP) describing all the statistical analyses to be completed will be finalized', 'prior to database lock. Unless otherwise specified, for numeric data, descriptive statistics will', 'include the number of patients with data to be summarized (n), mean, standard deviation (SD),', 'median, minimum (min), and maximum (max). Categorical data will be presented using frequency', 'counts and percentages. All statistical tests will be conducted at a 2-sided significance level of 5%', 'unless otherwise specified.', '6.2', 'Disposition of patients', 'Patient disposition will be summarized for the study, along with reasons for early termination.', 'Numbers (%) of patients in each analysis population will be tabulated.', '6.3', 'Protocol deviations', 'All protocol deviations will be reviewed and documented before database lock. Protocol deviations', 'will be recorded by the site staff, and study monitor. Major protocol deviations will be defined in the', 'SAP before unblinding the study.', '6.4', 'Analysis populations', 'Three analysis populations are defined for this study:', 'The randomized patient population will consist of all patients who are randomized;', 'The full analysis set will consist of all randomized patient who receive at least one dose of', 'study drug. The full analysis set will be used for the efficacy and safety analyses. Efficacy', 'analysis will be conducted according to the randomized treatment the patients receive, and', 'safety analysis will be conducted according to the actual treatment the patients receive;', 'The per-protocol set will consist of all patients in the full analysis set who do not have major', 'protocol deviations as defined in the SAP.', '6.5', 'Demographics and baseline characteristics', 'Demographics and baseline characteristics will be summarized by treatment for the full analysis set.', 'Demographics and baseline characteristics of the patient sample will be described using summary', 'statistics.', '6.6', 'Efficacy analyses', 'The primary endpoint is the change from baseline in the weekly average number of CSBMs during', 'the 12-week Treatment Period.', 'The secondary endpoints are defined as below:']\n\n###\n\n", "completion": "END"}